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Abstract: The extrapyramidal side effect parameters of typical and atypical antypsychotics were correlated with affinity 
chromatographic data determined on the melanin-based column. The chromatographic study was performed according to 
the hypothesis that extrapyramidal symptoms (EPS) as side effects of the use of antipsychotic drugs at clinically effective 
doses are correlated to the affinity of these drugs to neuromelanin. For that aim the polymerization product of L-DOPA 
(melanin) was immobilized onto aminopropyl silica and the binding efficiency of melanin towards antipsychotics has 
been determined. The results indicate that melanin based-column can be used to evaluate the risk of EPS of drug candi-
dates to antipsychotic drug therapy.
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INTRODUCTION
Antipsychotics drugs had a revolutionary, beneficial im-
pact on medical and psychiatric practice [1]. Unfortunately, 
the conventional drugs can cause extrapyramidal symptoms 
(EPS), likely to appear even with clinically effective doses. 
Because EPS have become an unavoidable consequence of 
the use of antipsychotics, the researchers for many years 
focused on  reducing their frequency [2]. Because of the risk 
of extrapyramidal adverse actions, antipsychotics were di-
vided into two basic groups: first generation – formerly 
known as typical, and second – newer generation, so-called 
atypical antipsychotics with lower risk of adverse ex-
trapyramidal symptoms [3]. This classification relates the 
EPS to substance-specific pharmacological profiles but does 
not consider the built-in-anticholinergic effect of some antip-
sychotics drugs. Hence, the classification is not much useful
in clinical practice.
The antipsychotics-neuromelanin binding interaction has 
received considerable attention as a potentially co-
responsible for extrapyramidal side effects [4, 5]. Numerous 
chromatography based methods were used in evaluating the 
binding of drugs to melanin [6-8]. Most recently, the new 
magnetic beads method for the estimation of potential of 
bioactive agents to evoke adverse effects due to melanin 
binding was proposed [9]. A significant linear correlation 
(R=0.8905) between the melanin binding efficiency data of 
seven antipsychotics and their risk of extrapyramidal side 
effects (EPS) assessed semiquantitatively, has been pre-
sented and proposed for further evaluation. In this study
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the affinity HPLC method with melanin immobilized on sil-
ica as a stationary phase was used as a potential tool for 
high-throughput screening (HTS) in preselection of drug 
candidates hopefully devoid of EPS side effects that can be 
useful in drug research and development process. The de-
tailed analysis of typical and atypical psychotropic drugs was 
performed and described here.
EXPERIMENTAL
Chemicals
Amisulpride, clozapine, 3,4-dihydroxy-L-phenyl-alanine 
(L-DOPA), N-(3-dimethylaminopropyl)-N-ethyl-carbodii-
mide hydrochloride (EDC), cis-(Z)-flupenthixol dihydro-
chloride, fluphenazine hydrochloride, haloperidol, N-
hydroxysulfosuccinimide sodium salt, perphenazine, pimoz-
ide, risperidone, sertindole, sodium phosphate dibasic were 
purchased from Sigma-Aldrich (Stainhaim, Germany). Ben-
peridol, bromperidol, as a European Pharmacopoeia Refer-
ence Standards, olanzapine, as a United States Pharmaco-
poeia Reference Standard and zuclopentixol hydrochloride, 
as a British Pharmacopoeia Chemical Reference Substance 
were purchased from LGC Promochem (Wesel, Germany). 
Perazine dimalonate was from LGC GmbH Biotechnolo-
giepark Luckenwalde (Germany) and quetiapine was from 
Chemicals Inc. (Toronto, Canada). The structural formulae 
of the studied drugs are given in Fig. (1).
Methanol, orthophosphoric acid and 2-propanol of chro-
matographic purity were all purchased from POCh (Gliwice, 
Poland). Water used in the study was prepared using a Milli-
Q Water Purification System (Millipore, Bedford, MA, 
USA). The aminopropyl silica (APS) stationary phase with
pore size 300 Å and particle size 7"m (Nucleosil 300-7 NH2)
was purchased from Macherey-Nagel (Düren, Germany).
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Preparation of Melanin-based Stationary Phase
The polymerization product of L-DOPA was immobi-
lized onto aminopropyl silica (APS) particles as follows. A 
15 mg sample of L-DOPA was dissolved in 3 ml of 25 mM 
potassium phosphate buffer (pH 6) and left to stand at ambi-
ent temperature for 7 days. A 150-mg portion of APS was 
rinsed three times with 5 ml of 25 mM potassium phosphate 
buffer (pH 6) and centrifuged. Next, 1 ml of the melanin 
solution (2.5 mg/ml of polymerization product of L-DOPA) 
was diluted in 2 ml of 25 mM potassium phosphate buffer 
(pH 6) with addition of 250 µl of  solution of EDC and NHS 
(1 mg/ml). The resulting solution was stirred for 10 min and 
then added to a centrifuge tube with the previously activated 
APS. The mixture was then rotated at 250 rpm in an orbital 
shaker for 24 h at ambient temperature. Next, the mixture 
was centrifuged at 1500 rpm for 5 min and the supernatant 
was discarded. Then, 20 ml of 1M hydroxylamine was added 
and shaken for 30 min at 4C. The resulted end-capped mela-
nin-coated silica was rinsed three times with 5 ml of 15% 
methanol solution. Then, the suspension of melanin-APS 
was placed in a glass column with inner diameter of 5 mm 
and length of 20 mm (5/20 Tricorn, GE Healthcare Bio-
Science AB/Amersham Biosciences, Freiburg, Germany) 
and allowed to settle. The fittings on the Mel-APS column 
were tightened and the column was washed with metha-
nol:water 60:40 (v/v) for 3 h and with 2-propanol:water 
20:80 (v/v) for 1 h using a chromatographic pump providing 
solvent flow rate of 0.4 ml/min.
Chromatographic Binding Studies to Melanin-based Sta-
tionary Phase
The retention times, tR, of the studied antipsychotics 
drugs by the melanin column were determined in isocratic 
mode with mobile phase consisting of 2-propanol:25 mM 
sodium phosphate buffer (pH 6.8) 13:87 (v/v), with flow rate 
of 0.6 mL/min. All the measurements were done in triplicate 
with UV multiwave-length detection and sample injection 
volume of 5 µL. The Shimadzu (Kyoto, Japan) chroma-
tographic system was composed of two solvent pumps (LC-
20AD), autosampler (SIL-20A), diode array detector (SPD-
M20A), column oven (CTO-20AC) and degasser DGU-
20A3.
RESULTS AND DISCUSSION
The physical and chemical interpretation of the interac-
tion that takes place inside the reversed-phase based column 
is relatively simple. The use a set of quantitatively compara-
ble retention parameters from RPLC and structural descrip-
tors allows for obtaining quantitative structure-retention rela-
tionships (QSRR) models that can be often successfully 
transformed into the quantitative structure-activity relation-
ships (QSAR). However, this study showed some difficulties 
in correlating the affinity chromatographic retention data for 
a set of antipsychotic drugs determined by HPLC with a col-
umn packed with melanin immobilized on silica support and 
the reported extrapyramidal symptoms parameters. The cor-
relations studied concerned the extrapyramidal motor side 
effects scale (EPS) and their number needed to harm (NNH). 
The calculated scales are relative to clozapine, which has the 
lowest EPS rate of all the studied antipychotics [10]. The 
EPS index was evaluated by co-medication with an anticho-
linergics - biperiden. NNH comprises the number of patients 
required to observe an additional case of EPS in relation to 
clozapine as a reference substance [10]. Also, the correla-
tions between the retention data and odds ratio (ODS) of 
EPS, as a quantitative assessment of the EPS-inducing po-
tency for each antipsychotic substance, were evaluated. The 
ODS have become widely used in medical practice as a con-
venient interpretation factor in case-control studies [11].
The meaningless correlation between the chroma-
tographic retention of set of 14 antipsychotics, including five 
so-called ‘atypical’ drugs (amisulpride, olanzapine, quetiap-
ine, risperidone, sertindole) and 9 ‘typical’ agents (benperi-
dol, bromperidol, flupentixol, fluphenazine, haloperidol, 
perazine, perphenazine, pimozide, zuclopentixol) and their 
side effects associated with the prescription of the drugs 
were observed (Fig. 2). The best, but still unsatisfactory rela-
tionships were found for chromatographic retention data 
determined on the melanin-based column and NNH (R = 
0.5459). The low correlations are certainly due to diverse 
structures of antipsychotic drugs and their physical and 
chemical properties, which are directly related to their chro-
matographic behavior. 
The low significance correlations are useless. Thus, we 
continued our research to find the best fitting of chroma-
tographic data to the EPS, ODS or NNH parameters. The 
analysis of relationships between the chromatographic reten-
tion time and extrapyramidal indexes were of  particular in-
terest. The further study was divided into five parts for dif-
ferent derivatives.
Aromatic Heterocycles Containing Piperazine Moiety
Overall, the aromatic heterocycles have the potential to 
interact with binding sites of biomolecules through a variety 
of bonding forces. They can interact through hydrophobic 
and van der Waals interactions, while the heteroatoms, such 
as nitrogen or sulphur, present in the structure could interact 
by hydrogen or ionic bonding. The performed relationships 
between the chromatographic retention data of a set of het-
erocyclic neuroleptics and either EPS, ODS or NNH showed 
the influence of position of the heteroatoms in the aromatic 
ring onto the interaction with immobilized melanin as the 
stationary phase. However, the much better correlation be-
tween the retention time and the EPS was observed for aro-
matic heterocycles containing piperazine moiety (Table 1). 
The reported structure-activity relationships (SAR) study 
proved that the distance between nitrogen from both 
piperazine and aromatic ring is responsible for neuroleptic 
activity [1]. The optimal distance for that activity is deter-
mined by three carbon atoms chain. Unfortunately, the high 
antipsychotic activity is correlated with high values of EPS 
and ODS parameters (Table 2). Except of that, the 
piperazine-1-ethanol moiety has the crucial role for the high 
EPS value (flupenthixol, fluphenazine, perphenazine and 
zuclopenthixol), as opposed to methyl substituent in 
perazine. However, the highest extrapyramidal side effects 
were observed for tricyclic neuroleptic drugs, such as flupen-
tixol and zuclopentixol. Based on their structures, one can 
assume that the double bound in carbon chain between the 
piperazine and tricyclic structure is probably responsible for 
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Fig. (2). Relationships between the chromatographic retention (tR) of antypsychotic drugs determined on immobilized melanin column and 
the risk of extrapyramidal symptoms (EPS) with reference to clozapine, odds ratio (ODS) of EPS relative to treatment with clozapine and 
NNH - the number of patients required to observe an additional case of EPS in relation to the reference drug clozapine. 
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Table 1. The equations and correlation coefficients of the relatioships between the chromatographic retention time of studied an-
typsychotics developed on the melanin column and their extrapyramidal side effect parameters: risk of extrapyramidal 
symptoms (EPS) with reference to clozapine, odds ratio (ODS) of EPS relative to treatment with clozapine and NNH- the 
number of patients required to observe an additional case of EPS in relation to the reference drug – clozapine
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Table 2. The extrapyramidal side effect parameters of studied drugs: risk of extrapyramidal symptoms (EPS) with reference to 
clozapine, odds ratio (ODS) of EPS relative to treatment with clozapine and NNH - the number of patients required to ob-
serve an additional case of EPS in relation to the reference drug – clozapine [1] and retention times measured on the 
melanin HPLC column. The retention time of clozapine  – 1.96 min
Antipsychotic Drug EPS Odds Ratio NNH tR [min]
Quetiapine 2 2.1 46 2.15
Olanzapine 4 3.1 25 0.57
Perazine 7 4.1 16 31.54
Sertindole 11 6.8 9.3 40.50
Amisulpride 14 9.1 6.9 4.19
Risperidone 17 11.0 5.8 27.52
Pimozide 23 12.2 4.3 24.77
Fluphenazine 22 14.7 4.5 19.54
Zuclopenthixol 27 15.2 3.7 45.55
Perphenazine 25 16.8 4.0 24.77
Flupentixol 26 18.4 3.8 19.90
Haloperidol 29 20.5 3.5 18.49
Bromperidol 34 26.2 2.9 20.00
Benperidol 61 79.1 1.6 30.87
the high intensity of the side effect. Also, the substitution of 
an electron-withdrawing group (-F, -CF3) at position 2 in-
creases both antipsychotic efficacy and extrapyramidal side 
effects [1].
Non-flurinated and Fluor-containing Antipsychotics
Certain chemical groups of bioactive compounds, 
which are susceptible to metabolic enzymes, can be re-
placed by a halogen substituent. Of the four halogens, 
fluorine drugs have a prominent position. The electro-
negative nature of fluorine can generate hydrogen bonds 
from H-bond donors [12]. Hence, the fluorination of cer-
tain drugs can alter their physical, chemical, electronic 
and conformational properties, which finally can change 
the pharmacological and also the side effects of drugs. 
Based on data in Table 2, one can notice that high EPS 
values have the fluor-containing ‘typical’ antipsychotics,
with exception of perazine. 
The non-halogen-containing drugs, mostly ‘atypical’, 
reduce psychotic symptoms while producing few EPS [10]. 
These non-fluor-containing-drugs give the similar correla-
tions (in the range of 0.605-0.701) between chroma-
tographic retention determined on studied columns and 
extrapyramidal side effect parameters (Table 2). A poor 
correlation of chromatographic data with EPS values was 
obtained for fluor-containing-antipsychotics. It must be 
noted here that benperidol with the highest EPS value and 
average retention time appeared to be an outlier in the cor-
relation analysis. After the exclusion of that drug from fur-
ther analysis, much better correlations of the data were ob-
tained for the melanin column (Fig. 3). There is a nearly 
perfect correlation of retention time and NNH and a worse 
but still acceptable for EPS and ODS parameters. Curi-
ously, the relationships between retention data determined 
on melanin column and EPS and ODS have negative value 
of the slope -0.878 and -0.945 respectively. The results 
demonstrate that the fluor-containing-antipsychotics, unlike 
others, have a reverse relationship between affinity to the 
melanin and their extrapyramidal side effects. This contrary 
effect might probably be due to steric effects of fluorine 
atoms that can alter drug metabolism or enzyme substrate 
recognition [13]. Hence, the fluorine substitution into struc-
ture of a biologically active compound can cause unex-
pected changes in the biological activity due to the ability 
of these bulky atoms to occupy the binding site of molecu-
lar targets [12]. Moreover, the surprising reverse relation-
ship after exclusion of benperidol can be explained by ‘po-
lar hydrophobic’ properties of fluorine-containing com-
pounds which can lead to changed affinity to natural recep-
tors. The fluorine substitution on the aromatic ring reduces 
its polarizability and increases the hydrophobic surface area 
of the molecule. Such dual nature of fluorine-containing 
drugs can lead to their unexpected chromatographic 
behavior.  
Non-sulfur-containing and Sulfur Containing Antipsy-
chotics
Most of the tricyclic antipsychotics have two benzene 
rings which are linked by sulfur and nitrogen atom. The nature 
of sulfur at position 5 of phenothiazines and thioxanthenes
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Fig. (3). Relationships between the chromatographic retention (tR) of fluor-containing antipsychotic drugs (excepting benperidol) determined 
on the melanin-based column and the risk of extrapyramidal symptoms (EPS) with reference to clozapine, odds ratio (ODS) of EPS relative to 
treatment with clozapine and NNH - the number of patients required to observe an additional case of EPS in relation to the reference drug 
clozapine. Analytes: bromperidol (1), haloperidol (2), flupenthixol (3), fluphenazine (4), pimozide (5), risperidone (6), sertindole (7).
influences their antipsychotic activity [1]. Also, the presence 
of sulfur causes a better correlation between the chroma-
tographic retention of the sulfur-containing antipsychotics 
and EPS than that for the non-sulfur containing drugs. 
CONCLUSION
For the new antipsychotics drug design it is important to 
evaluate the risk of side effects of drug candidates. Hence,
the analytical methods determining the binding of drugs to 
melanin should be evaluated according to hypotheses that 
extrapyramidal symptoms are correlated to neuromelanin 
affinity of these drugs. 
Compared to older conventional antipsychotics, the 
newer ‘atypical’ drugs are characterized by decreased  inci-
dence of EPS or other movement disorders at doses produc-
ing antipsychotic effects. However, the importance of EPS in 
the context of treatment of psychosis tends to be underesti-
mated [3]. Moreover, the dichotomous classification as a 
‘typical’ and ‘atypical’ antipsychotics appears to be dispen-
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used EPS parameter is appropriate because it does not pro-
vides clinically useful distinction among the currently used 
antipsychotics [10]. The new NNH parameter describing the 
number needed to harm, instead of EPS, may be of help in 
risk consideration for antipsychotic treatment. 
Based on our result, the following conclusions can be 
drawn. First, there are evident relationships between the 
antipsychotics binding to melanin and their extrapyrami-
dal motor side effects. The weak and sometimes meaning-
less correlations observed were probably due to non-
homo-geneous structurally sets of compounds considered, 
comprising of benzepines, phenothiazines, thioxanthenes, 
butyrophenone and other heterocyclic antipsychotics. 
Hence, the significant differences in chromatographic 
behavior were unavoidable. Surprisingly enough, regard-
less of that, the NHH proved to be the most ‘robust’ side 
effect index for miscellaneous structures of studied drugs, 
with correlation coefficient  (0.575-0.702). Hence, it can 
appear to be more effective not only in optimizing the 
treating of psychotic disorders but also in predicting affin-
ity to melanin to evaluate the risk of adverse effects of 
antipsychotic drugs. 
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